Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.

Caris Detect leverages Caris' industry-leading molecular profiling data, which has surpassed one million cases processed and produced more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify subtle biological signals associated with early-stage cancers with unprecedented resolution. 

Achieve 1 is evaluating Caris Detect across a broad population of patients, assessing its ability to detect multiple cancer types at early stages using a blood draw. For the undiagnosed cohort, which consisted of 1,505 samples, we utilized blood draws from subjects who had screening or symptomatic screening, a population reflecting a higher likelihood of cancer than the general population. We followed 22.5% of the subjects for approximately one year following their blood draw. Of these, 121 subjects had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer, representing a healthy population.

• No comments yet. Be the first to comment!